AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
232.91
-0.96 (-0.41%)
At close: Nov 19, 2025, 4:00 PM EST
231.98
-0.93 (-0.40%)
After-hours: Nov 19, 2025, 7:58 PM EST
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,084,436
Profits / Employee
$42,691
Market Cap
411.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABBV News
- 1 day ago - AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma - PRNewsWire
- 1 day ago - It's Best Time In 10 Years To Lock In Income: Our Picks - Seeking Alpha
- 1 day ago - Global drugmakers rush to boost US presence as tariff threat looms - Reuters
- 5 days ago - AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript - Seeking Alpha
- 6 days ago - AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ - PRNewsWire
- 7 days ago - AbbVie Shares Rise To Intraday High After Key Trading Signal - Benzinga
- 7 days ago - Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders - GlobeNewsWire
- 7 days ago - Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence - PRNewsWire